Indaptus reports Q3 loss per share $2.98, cash $5.8M; pauses enrollment pending Decoy20 combo efficacy

Indaptus Therapeutics, Inc.

2025-Q3 EPS reported -$18.48

Q3 2025 loss per share $2.98 vs $9.04 YoY; cash $5.8M at Sept 30, expected to fund into Q1 2026.
Completed Safety Lead-In cohort, dosing 6 participants with Decoy20 + tislelizumab; 3 stable disease, 2 remain on study.
Enrollment paused pending additional efficacy evaluation and assessment of next development options.
Raised $2.3M via ATM in September 2025; converted $5.7M promissory notes into stock/warrants in July.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.